Micropuncture and morphologic studies were performed in six groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney.
Introduction
Reduction of renal mass leads to structural and functional hypertrophy, with marked increases in the perfusion and filtration of the remaining nephron units (1) (2) (3) . Hyperfiltration in these nephrons results from elevations in the mean glomerular transcapillary hydraulic pressure gradient (Apl)' and plasma flow rate (QA). In the remnant kidneys of rats subjected to extensive renal ablation, these elevated glomerular capillary pressures and flows are associated with progressive proteinuria and eventual glomerular sclerosis (3, 4) .
Therapeutic interventions which attenuate these adaptive glomerular hemodynamic changes slow the development ofglomerular structural injury. Dietary protein restriction, which lowers the single nephron (SN) glomerular filtration rate (GFR) by normalizing glomerular capillary pressures and flows, retards the development of glomerular sclerosis in the hyperfiltering kidneys of rats with reduced renal mass (5) , diabetes mellitus (6) , and mineralocorticoid-induced hypertension (7) . Alternatively, selective reduction of AP with the angiotensin I (AI)-converting enzyme inhibitor enalapril lessens glomerular injury in rats with reduced renal mass (4) or experimental diabetes (8) . Central to each of these therapies is normalization of AP, since enalapril therapy induces no significant change in QA or in SNGFR (4, 8) .
Systemic hypertension, when transmitted to the glomerular capillary network, results in glomerular capillary hypertension. Elevated systemic pressures are accompanied by elevated glomerular capillary pressures in several experimental models of hypertensive renal disease, including renal ablation (3, 4) , postsalt hypertension (9) , and chronic mineralocorticoid administration (7) . While the foregoing enalapril studies suggest that systemic blood pressure therapy resulting in normalization of AP protects against eventual glomerular injury, it remains unclear whether other antihypertensive regimens would be equally protective. In 1976, Purkerson and co-workers reported that normalization of systemic blood pressure in remnant kidney rats treated with reserpine, hydralazine, and hydrochlorothiazide afforded only modest protection against glomerular structural injury (10). Recent reports suggest that a similar regimen confers protection in certain models of hypertensive renal disease (1 1, 12) , but fails to protect against glomerular injury in others (13, 14) .
In designing the present study, we reasoned that systemic hypertension must be transmitted to the glomerular capillary network in order for glomerular structural injury to eventuate. Consequently, reduction in systemic pressure must result in re-duction in glomerular capillary pressure in order to confer protection upon glomeruli at risk for eventual sclerosis. We further reasoned that a conventional triple drug regimen, containing both vasodilators and a diuretic, might be a potent stimulus to the renin-angiotensin system, and accordingly, cause efferent arteriolar vasoconstriction sufficient to maintain the high glomerular capillary pressures seen in untreated rats with reduced renal mass. Accordingly, we compared the glomerular hemodynamic and morphologic effects of systemic blood pressure control with reserpine, hydralazine, and hydrochlorothiazide with those in untreated remnant kidney rats, and with those seen in rats treated with enalapril.
Methods
Six groups of male Munich-Wistar rats with initial weights of 220-250 g were used in these studies. All rats were subjected to five-sixths renal ablation by removal ofthe right kidney and infarction of approximately two-thirds of the left kidney by ligation of two or three branches of the left renal artery. All groups were fed standard rat chow (Wayne Rodent Blox, Allied Mills, Chicago, IL) containing -24% protein by weight.
Groups 1 and 4 received no specific therapy. Groups 2 and 5 were treated with the Al-converting enzyme inhibitor, enalapril (Merck, Sharp & Dohme, West Point, PA), at a dose of 50 mg/liter in the drinking water starting 1 wk after ablation. Groups 3 and 6 received reserpine (5 mg/liter), hydralazine (80 mg/liter), and hydrochlorothiazide (25 mg/ liter) (Sigma Chemical Co., St. Louis, MO) in the drinking water starting 1 wk after ablation. Pilot studies established that all three drugs were necessary to control systemic blood pressure at levels comparable to those achieved with enalapril. Groups 1-3 (each n = 8) underwent micropuncture study 4 wk after ablation. Groups 4-6 (each n = 12) were followed for 12 wk after ablation, at which time the remnant kidneys were perfusion-fixed for evaluation of structural damage.
Systolic blood pressure was measured weekly in all rats, in the conscious state, by the tail cuff method ( 15) . 24-h urinary total protein excretion was measured in groups 4-6 at 3, 6, 9, and 12 wk after ablation. Plasma renin concentrations were measured in separate groups ofshamoperated rats, and in rats with five-sixths nephrectomy receiving either no treatment, enalapril, or reserpine, hydralazine, and hydrochlorothiazide (each n = 7). Rats were decapitated and trunk blood collected in EDTA 4 wk after operation.
Micropuncture studies. For micropuncture study, rats were anesthetized with Inactin (100 mg/kg body wt, i.p.) and placed on a temperature-regulated micropuncture table. Immediately after the induction of anesthesia, the left femoral artery was catheterized with PE-50 polyethylene tubing, followed by a baseline collection of 210 ul of arterial blood. This arterial catheter was used for subsequent periodic blood sampling and estimation of mean arterial pressure (AP). AP was monitored with an electronic transducer (model P23Db; Statham Instruments Div., Gould Inc., Oxnard, CA) connected to a direct-writing recorder (model 7702B; Hewlett-Packard Co., Palo Alto, CA). Polyethylene catheters were also inserted into the left and right jugular veins for infusions of inulin and plasma. Intravenous infusions of isoncotic rat plasma and 4% inulin solution in 0.9% NaCl were started at rates of 6.0 and 1.2 ml/ h, respectively. The left kidney was exposed by a subcostal incision and separated from the adrenal gland and the surrounding perirenal fat. The left kidney was suspended on a lucite holder, and its surface illuminated with a fiberoptic light source and bathed with isotonic NaCl.
Since the plasma volume of rats prepared for micropuncture is reduced by -20% (16), the following protocol for maintaining the euvolemic state was employed. After insertion ofthejugular catheters, isoncotic rat plasma was infused for '-25 min, in a total amount equal to 1% of body weight, followed by a reduction in infusion rate to 0. 41 ( 17) .
Morphology. Rats in groups 4-6, followed for 12 wk after ablation, were processed for morphologic examination. Kidneys were fixed by perfusion at the measured arterial pressure with 1.25% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4). After perfusion-fixation, one or two 3-4 mm thick coronal sections through the mid-portion of the remnant were postfixed in 4 g/100 ml buffered formaldehyde solution and proc essed for light microscopy through paraffin embedding. Sections Fig. 1 , systolic blood pressure in group 4 rats averaged 177±7 (SEM) mmHg by the second week after ablation, and hypertension was sustained or tended to increase during the final weeks of the observation period. Despite equally extensive renal ablation, the development of systemic hypertension was prevented in rats treated with either enalapril or with triple drug therapy. Systolic blood pressure values were comparable in groups 5 and 6, and were controlled to levels within the normal range.
Micropuncture studies. Mean values for body weight, Hct, plasma urea nitrogen concentration, whole kidney GFR, AP, SNGFR, and the pressures, flows, and resistances governing glomerular ultrafiltration for groups 1-3 are summarized in Table  I . Treatment with triple drug therapy, but not with enalapril, resulted in slightly lower values for body weight (P < 0.01) and Hct (P < 0.01) as compared with untreated group 1 rats. Mean AP under anesthesia was markedly elevated in untreated group 1 rats, averaging 154±8 mmHg, whereas hypertension was absent in groups 2 (107±2 mmHg) and 3 (107±3 mmHg) (both P < 0.005 vs. group 1). Despite the lower renal perfusion pressure in the treated groups, values for remnant kidney GFR did not differ significantly among the three groups, averaging 0.60±0.07 ml/min in group 1, 0.54±0.05 ml/min in group 2, and 0.61±0.08 ml/min in group 3 (NS). All three groups of rats were azotemic, with values for plasma urea nitrogen concentration averaging 56±6 mg/100 ml in group 1, 55±3 mg/100 ml in group 2, and 60±4 mg/100 ml in group 3 (NS). Despite comparable reduction in renal mass, and equivalent control of systemic arterial blood pressure, the rats treated with enalapril and with triple drug therapy exhibited strikingly different glomerular hemodynamic patterns from one another as well as from the untreated group 1 rats. In accord with our previous study of enalapril therapy in rats with reduced renal mass (4), control ofsystemic blood pressure in enalapril-treated group 2 rats was associated with prevention of glomerular capillary hypertension, so that Pcc (53±1 mmHg) and therefore AP (36±1 mmHg) remained at levels near those seen in intact, two-kidney rats (24) . SN hyperfiltration in these group 2 rats was therefore maintained primarily by the elevated QA, but also by a significant increment in Kf. Because all animals were in filtration pressure disequilibrium, with values for AP greater than efferent arteriolar oncotic pressure, unique values for Kf were calculable. In enalapril-treated group 2 rats, Kf averaged 0.0965±0.0133 nl/ (s mmHg), a value significantly higher than that observed in untreated group 1 rats (0.0492±0.0051 nl/[s. mmHg]) (P < 0.005). Maintenance of the high glomerular plasma flow rate in these rats reflected marked arteriolar vasodilatation, with a significant reduction in afferent, efferent, and total arteriolar resistances. Presumably, reduction in efferent arteriolar resistance resulted in reduction of PGc and therefore AP in this group.
Values for afferent and efferent arteriolar plasma protein concentration and colloid osmotic pressure did not differ from the untreated group 1 animals.
Triple drug therapy with reserpine, hydralazine, and hydrochlorothiazide in group 3 rats resulted in control of systemic blood pressure comparable to that seen in the enalapril-treated group 2 rats, but the effects on glomerular hemodynamics were strikingly different. In groups 2 and 3, reduction of systemic blood pressure resulted in a significant reduction in afferent arteriolar resistance (Table I) , possibly due to autoregulation. However, efferent arteriolar resistance was not different from that seen in the untreated group 1 rats. Accordingly, glomerular capillary hydraulic pressure remained at levels comparable to those seen in untreated group 1 rats. In group 3 rats, SN hyperfiltration was due to elevations of QA and AP, a pattern similar to that seen in the untreated group 1 rats. In these rats treated with triple drug therapy, in marked contrast to the enalapriltreated rats, control of systemic blood pressure was not associated with reduction in PGC or AP, or elevation of Kf.
Activity ofthe renin-angiotensin system in the various groups 4), and almost no increase in protein excretion thereafter. Despite equivalent control of systemic hypertension, the failure oftriple drug therapy to control glomerular hypertension in group 6 rats allowed the development of progressive proteinuria. In this group, urinary protein excretion rates were lower than those seen in untreated group 4 rats at the initial determination (3 wk after ablation, Fig. 2 ), but thereafter rapidly rose to levels indistinguishable from those seen in the untreated group 4 rats. Despite continued control of systemic hypertension (Fig. 1) , proteinuria in the triple drug-treated group 6 rats averaged 110±7 mg/d by 12 wk after five-sixths nephrectomy. Structural alterations. At the end of the 1 2-wk observation period, untreated animals showed prominent and widespread glomerular alterations characterized by focal and segmental collapse of capillaries, hyaline deposition, and adhesion of the glomerular tuft to Bowman's capsule (Fig. 3 A) . These areas of collapse often contained vacuolated cells surrounded by basement membrane and matrix material. Focal and segmental obsolescence of the glomerular capillary tuft as described above was present in 22.5±4.4% of glomeruli in the untreated group 4 rats. In addition, occasional glomeruli in untreated animals showed microaneurysm formation identical in appearance to the lesions described previously in mineralocorticoid-salt hypertension (7) . ipithelial cell abnormalities with increased numbers of lysosomes (reabsorption droplets) and cytoplasmic blebs were often observed. Occasional areas of tubule atrophy, interstitial fibrosis and mild chronic inflammation, and cast formation in distal tubules and ascending thick segments of the loop of Henle were observed in association with the glomerular abnormalities. Arteries and arterioles showed rare hypertrophic changes oftheir media with minimal hyaline deposition. In contrast, animals in group 5 treated with enalapril showed minimal structural alterations ( Fig. 3 B) ; the frequency of segmental glomerular lesions was reduced on average to 1.4±0.2%, a value significantly lower than that seen in untreated group 4 animals (P < 0.01). Tubule, interstitial, and vascular alterations were virtually absent in this group. Despite equivalent control of systemic blood pressure, animals in group' 6 receiving triple drug therapy (Fig. 3 C) developed glomerular, tubule, and interstitial lesions similar in frequency and severity to untreated rats; the frequency of glomerular lesions in this group was 24.5±2.5%, a value significantly higher than the average seen in enalapriltreated animals, (P < 0.01), but not different from that observed in' the untreated group 4 rats. 
Discussion
In the present study, monotherapy with enalapril, and triple drug therapy with reserpine, hydralazine, and hydrochlorothiazide were equally effective in controlling systemic hypertension despite the extensive reduction in renal mass. However, equivalent systemic blood pressure control in the two groups was associated with strikingly different glomerular hemodynamic consequences. In the untreated group 1 rats, afferent and efferent arteriolar vasodilatation resulted in elevation of the glomerular capillary plasma flow rate. While both afferent and efferent arteriolar resistances were much lower than those seen in normal rats (24) , the proportionately greater reduction in afferent arteriolar resistance allowed elevation of the glomerular capillary hydraulic pressure. In the enalapril-treated group 2 rats, normalization of mean arterial pressure resulted in even further afferent arteriolar vasodilatation. However, the concomitant reduction in efferent arteriolar resistance offset the reduction in afferent arteriolar resistance, so that the glomerular capillary hydraulic pressure was reduced to near normal levels. In contrast, in group 3 rats treated with the triple drug regimen, the reduction in afferent arteriolar resistance associated with normalization of systemic blood pressure was not accompanied by a proportional reduction in efferent arteriolar resistance. The combination of vasodilation and a diuretic, both of which are known to elevate plasma renin levels in humans (25, 26) , preserved angiotensin II-induced efferent arteriolar tone in this group. Accordingly, the glomerular capillary hydraulic pressure was maintained at the same high level as was seen in the untreated group I rats. Therefore, control of systemic hypertension does not invariably result in control of intraglomerular hypertension, a finding recently reported in other experimental models as well (13, 14) .
In all three groups of rats, intrarenal vasodilatation resulted in elevation of the glomerular capillary plasma flow rate, which contributed to the SN hyperfiltration. The renal vasodilatory response to enalapril may result from several potential mechanisms. Despite the subnormal plasma renin (and presumably angiotensin II) levels in the untreated rats, the remnant kidney exhibits enhanced responsiveness to angiotensin 11 (27) , a hemodynamic effect which would be reversed by enalapril therapy.
Aiternatively, the antihypertensive and renal effects of enalapril may relate to the multiple non-renin-mediated actions of converting enzyme inhibitors (28) . In the untreated group 1 and triple drug-treated group 3 rats, SN hyperfiltration was due to elevations in both the glomerular capillary plasma flow rate and the glomerular transcapillary hydraulic pressure gradient. In both of these groups, the Kf was lower than that seen in normal rats (24) . While the mechanism of the decrease in Kf is not clear, an inverse relationship between AP and Kf has been demonstrated in a comprehensive analysis of the determinants of glomerular filtration (29) . In the current setting, the reduction of Kf very likely represents damage to the glomerular capillary wall secondary to the high hydraulic pressures and flows within the glomerular capillary. In contrast, in the enalaprilLtreated group 2 rats, Kf was significantly higher than in the other two groups. This maintenance of Kf at normal levels presumably reflects preservation of glomerular capillary wall structural integrity in the presence of near-normal capillary hydraulic pressures, and preservation of Kf may contribute to long-term maintenance of SNGFR as well. In addition, the increase in Kf may reflect inhibition of the endogenous action of angiotensin II, a peptide known to lower Kf under a variety of physiological and pathophysiological circumstances (30, 31 (14) .
Reduction in glomerular capillary hydraulic pressure may be achieved by several different hemodynamic mechanisms. In the spontaneously hypertensive rat, relative afferent arteriolar vasoconstriction prevents transmission of high systemic pressures to the glomerular capillary network, thereby preventing increases in glomerular capillary hydraulic pressure (33, 34) . When this relative afferent vasoconstriction is abolished by uninephrectomy (35) or induction of diabetes (36) , glomerular capillary hydraulic pressure increases. In our remnant kidney rats, and in the hyperfiltering kidneys of normotensive diabetic rats (8) (10) and mineralocorticoid-induced hypertension (13 (39) .
The current study raises several important questions concerning the role of control of systemic hypertension in the man-agement ofpatients with progressive renal disease. Recent studies have provided encouraging evidence that control of systemic blood pressure may slow the progressive course of renal disease due to diabetes mellitus (40, 41) , essential hypertension (42) , and intrinsic renal disease (43-44). We would suggest, however, that more specific knowledge of the intrarenal hemodynamic effects of the numerous antihypertensive drugs available to the clinician is needed before a beneficial renal outcome may be confidently predicted. In particular, we must be aware of the potential intrarenal consequences of blood pressure reduction in those patients with clinically apparent reduction in functioning nephron number, since these patients are at highest risk offurther hemodynamically mediated glomerular injury.
